Market Checkup: Sept. 16, 2013
In this edition of the Motley Fool's health-care show Market Checkup, analysts David Williamson and Max Macaluso look at the big pharma companies circling biotech ViroPharma, a cancer drug granted priority review by the FDA, and a serious patent issue that affects fish oil drugmakers GlaxoSmithKline and Amarin.
Retiring rich can be easy
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth but also winning strategies that every investor should know. Click here to grab your free copy today.
The article Market Checkup: Sept. 16, 2013 originally appeared on Fool.com.
David Williamson owns shares of Amarin (ADR). Max Macaluso, Ph.D. and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.